Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 is drawing significant interest across the industry.
Eli Lilly shares rise after orforglipron beats Novo's drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Sundaram Alternates Invests Rs 80 Crores in Vijay Raja Homes, Reinforcing Trust Built Over 75 Plus Years
- SCOTUS will take up a key climate case.
- EXCLUSIVE: CBFC replaces ‘Donald Trump’ with ‘Pump Trump’, ‘Dawood Ibrahim’ with ‘Pakistan Don’ in Anurag Kashyap’s Kennedy
- Historic U.S.-Japan Investment Projects Set to Boost American Energy Capacity
Source: Original →